Company / Cash & Equivalents
Viatris Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.3B
FY2025
5-year range
$701.2M / $1.3B
FY2021-FY2025
Trend
+80.0%
vs FY2024
Sector context
#16 of 207
Health Care
What the data says
Among 207 Health Care companies, Viatris is in the top 8% for cash & equivalents. Cash & Equivalents has fluctuated over the past 8 years, ranging from $388M in FY2018 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +22.7%. Top quartile in the Health Care sector.
Improved from $992M to $1.3B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +23.5%
- 5-Year CAGR
- +22.7%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 207This company $1.3B Sector average $669.5M
▼
+97.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +22.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 80.0% year-over-year.
- Ranks #16 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +80.0% |
| FY2024 | $734.8M | -25.9% |
| FY2023 | $991.9M | +41.5% |
| FY2022 | $701.2M | -17.0% |
| FY2021 | $844.4M | +77.5% |
| FY2020 | $475.6M | +0.0% |
| FY2019 | $475.6M | +22.5% |
| FY2018 | $388.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026